[{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","route":"/companies/taiho/","commit":"067761977c","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on every remaining company","file":"src/data/spikes/cholangiocarcinoma.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.taiho.co.jp/en/\" }]"}]},{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","route":"/companies/taiho/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","route":"/companies/taiho/","commit":"06899fbdf4","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: hepatocellular carcinoma, biliary tract cancer, neuroendocrine tumours (deep, with structured outcomes, dosing, toxicity, regulatory","file":"src/data/spikes/cholangiocarcinoma.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"companies"},{"field":"cancers"}]}]